Drugs in development · updated 30 October 2026
Glioma: drugs in development
As of 30 October 2026 there are 182 active clinical trials (recruiting or ongoing, phases I–III) on 184 drugs for glioma. 81 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
Sorted by most advanced phase and number of active trials. Showing 40 of 81 drugs.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| TemozolomideTemodal, Temodar | III | 36 | NCT00978458 |
| TrametinibMekinist®, Spexotras® | II–III | 6 | NCT07440290 |
| Bevacizumabavastin, MVASI | III | 5 | NCT06888817 |
| DabrafenibTafinlar®, Finlee® | II–III | 5 | NCT07440290 |
| LomustineCCNU, Gleostine® | III | 5 | NCT00887146 |
| EntrectinibRozlytrek® | II–III | 3 | NCT05770544 |
| VorasidenibVoranigo® | III | 3 | NCT04164901 |
| 18F-DOPA18F-FDOPA, Fluorodopa F 18 | III | 2 | NCT05512403 |
| Aminolevulinic Acid5-Aminolevulinic acid Hydrochloride, Gliolan | III | 2 | NCT06160492 |
| DexamethasoneDexametasone, Dextenza | III | 2 | NCT06888817 |
| VemurafenibZelboraf® | II–III | 2 | NCT05768178 |
| VincristineVincristin, Oncovin [vincristine] | III | 2 | NCT00887146 |
| CapmatinibINC280, Tabrecta® | II–III | 1 | NCT06988475 |
| CobimetinibCotellic® | II–III | 1 | NCT05768178 |
| DordaviproneONC201, Modeyso® | III | 1 | NCT05580562 |
Sorted by most advanced phase and number of active trials. Showing 15 of 103 drugs.
All 184 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Glioblastoma 245 drugs
- Brain Neoplasms 190 drugs
- Astrocytoma 64 drugs
- Medulloblastoma 77 drugs
- Gliosarcoma 34 drugs
- Ependymoma 56 drugs
- Neoplasm 671 drugs
- Oligodendroglioma 26 drugs
- Diffuse Intrinsic Pontine Glioma 40 drugs
- Melanoma 352 drugs
- Primitive neuroectodermal tumor 31 drugs
- Metastasis 493 drugs
Broader categories
- Glandular and epithelial neoplasm 12 drugs
- Neuroectodermal tumor 3 drugs
- Germ cell and embryonal neoplasms 35 drugs
- Nerve tissue neoplasm 4 drugs
- Neuroepithelial neoplasm 4 drugs
- Neoplasm 671 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D005910 “Glioma”. Prevalence: Orphanet.